ライフサイエンスコーパス: effector phase

1 recipient" skin to induce GVH tissue damage (effector phase).

2 e chemokine plays a distinct role during the effector phase.

3 ted T helper cell production of IL-17 in the effector phase.

4 that LCs act during the priming and not the effector phase.

5 of memory cell precursors at the peak of the effector phase.

6 vents are critical for the regulation of the effector phase.

7 minal immune complex/complement/FcR-mediated effector phase.

8 secondary tissue damage in situ in the late, effector phase.

9 e, but not if IP-10 was depleted only in the effector phase.

10 ough cycloheximide (CHX) still triggered the effector phase.

11 required CD8 T cells during the priming and effector phase.

12 (+) T cells in the spleen and CNS during the effector phase.

13 ress allergic airway inflammation during the effector phase.

14 osteoclasts, and vascularization in the CIA effector phase.

15 , much less is known about what controls the effector phase.

16 sensitization, but is proallergic during the effector phase.

17 adaptive immune response and an inflammatory effector phase.

18 ed during both the initial sensitization and effector phase.

19 he function of immune T cells in vivo at the effector phase.

20 d apoptosis with or without MCP-1 during the effector phase.

21 rs that likely drive the disease through its effector phases.

22 Late addition of Tregs into the effector phase abolished their ability to suppress effec

23 -molecule inhibitor during the tissue-damage effector phase abrogates the clinical manifestation of d

24 sion of CTLA4Ig and donor alloantigen in the effector phase (after cardiac engraftment) resulted in l

25 During the effector phase, all the LCMV-specific IFN-gamma(+) CD4 T

26 , immune regulatory pathways can subvert the effector phase and enable tumor escape.

27 in lymphoid tissues at the waning end of the effector phase and microbial clearance.

28 The multiple roles of Argonautes in the RNAi effector phase and miRNA biogenesis and maturation sugge

29 recognized to play an important role in the effector phase and propagation of the immune response in

30 ory CD8(+) T cells appear to pass through an effector phase and then gradually down-regulate expressi

31 ne responses during both the priming and the effector phases and provides a strategy to overcome T(re

32 adaptive cellular subsets in the activation, effector phases, and target organ specificity of acute G

33 The effector phases are conveniently modeled by the K/BxN se

34 e timing of AICD, and thus the length of the effector phase, are regulated by transient expression of

35 aradigm defines a late checkpoint during the effector phase at which cognate interactions direct CD4

36 In contrast, IFN-gamma treatment during the effector phase attenuated disease.

37 with anti-PD-L1 antibody present during the effector phase but not during the priming culture.

38 ere established initially during the primary effector phase but were maintained for weeks, into the m

39 sis of murine allergic conjunctivitis at the effector phase, but not during the initial sensitization

40 at complement plays an essential role in the effector phase, but not the inductive phase, of RRV-indu

41 in antibiotic-pretreated mice undergo brief effector phase, but rapidly develop phenotypic (CD127(hi

42 n, though a role for this interaction in the effector phase cannot be ruled out.

43 ue damage when added to the skin co-culture (effector phase), concurrently with primed T cells.

44 ic CD8(+) T cells passed through an obligate effector phase, contracted more than 90% and gradually d

45 express surface activation markers, contain effector phase cytokine mRNAs, and contain perforin and

46 ne initiation (early blockade) or the immune effector phase (delayed blockade).

47 Induction-phase and effector-phase depletions of T cell subsets were perform

48 nd these changes are already manifest in the effector phase despite the presence of Ag-expressing den

49 TGF-beta at several different (including the effector) phases during the response.

50 fic monoclonal antibody (mAb) CC1 during the effector phase exhibited a reduced severity of trinitrob

51 +) T cells adoptively transferred during the effector phase fail to expand without DC, CD28 costimula

52 flammatory cytokines, results in a transient effector phase followed by the accelerated acquisition o

53 or-infiltrating lymphocytes are defective in effector phase function, demonstrating tumor-induced imm

54 ck) activation motif (Y394), thus inhibiting effector phase functions.

55 ring mice are deficient in either priming or effector phase functions.

56 At the effector phase, IFN-gamma production by transferred T ce

57 ing for self-antigen-specific T cells at the effector phase in target tissues.

58 ring the induction phase but also during the effector phase in the tumor microenvironment, implying a

59 that CD4 T cells from the early stage of the effector phase in which both the Ag and activation are o

60 e response was characterized by a protracted effector phase in which cytolytic activity in the lamina

61 More diverse elements are required for the effector phase, including components from the innate imm

62 demonstrated that blocking IL-10 during the effector phase increased not only the incidence and seve

63 d alpha2 were found to significantly inhibit effector phase inflammatory responses in animal models o

64 ersistence of viral Ag presentation into the effector phase is the key factor that determines the eff

65 In the effector phase, loss of CTLA-4 on Tfh cells resulted in

66 hich demonstrates an impact of Treg cells on effector phase manifestations.

67 vade host immunity at both the induction and effector phases Most studies have focused on tumor evasi

68 he contribution of mucosal mast cells to the effector phase of a secondary immune response to Trichin

69 disease (GVHD), but the role of APCs in the effector phase of acute GVHD is not known.

70 tes derived from spleens of males during the effector phase of adoptive EAE produced significantly hi

71 e data identify a novel role for CD28 in the effector phase of allergic airway inflammation and sugge

72 To study the role of CD28 in the effector phase of allergic airway inflammation, we devel

73 as a critical role in both the induction and effector phase of allergic airway inflammation.

74 sponsiveness and mucus production during the effector phase of allergic asthma.

75 een IL-4 and vasoactive mediators during the effector phase of allergic inflammation may both contrib

76 eating the critical immune components of the effector phase of allergic reactions to food.

77 allergic responses, also contributes to the effector phase of allergy.

78 umor microenvironment dominantly resists the effector phase of an anti-tumor T cell response, contrib

79 regulatory role for epidermal LCs during the effector phase of an inflammatory immune response in the

80 on of tumor cells, at both the induction and effector phase of antitumor immunity.

81 During the effector phase of apoptosis, caspase activation appears

82 endent and occurs prior to commitment to the effector phase of apoptosis, definitively ordering ceram

83 rocaspase-8 processing and activation of the effector phase of apoptosis.

84 ysteine proteases play a pivotal role in the effector phase of apoptosis.

85 te essential homeostatic pathways during the effector phase of apoptosis.

86 T and B lymphocyte-independent model of the effector phase of arthritis and is induced by well-defin

87 hat Bim potentially functions to repress the effector phase of arthritis by regulating the milieu of

88 esults argues that our focus on the terminal effector phase of arthritis in the K/BxN model will bear

89 mic delivery of poly(IC) on the inflammatory effector phase of arthritis using the collagen Ab-induce

90 sis of chemokines and their receptors in the effector phase of arthritis using the K/BxN mouse serum-

91 transfer, thereby focussing on the end-stage effector phase of arthritis, leap-frogging the initiatin

92 II expression appears to be important in the effector phase of arthritis, possibly by activating cyto

93 n addition, ICAM-1 also played a role in the effector phase of autoimmune diabetes because adoptive t

94 effective in preventing the insulitis or the effector phase of autoimmune diabetes.

95 and have implications for regulation of the effector phase of CD8+ T cell responses in tissue microe

96 is impacted by prolonged stimulation during effector phase of chronic infection, we adoptively trans

97 e inhibitory receptor PD-1 occurs during the effector phase of chronic viral infection.

98 that regulate inflammatory responses in the effector phase of CHS, we performed further investigatio

99 nd inflammatory KC hyperproliferation in the effector phase of CHS.

100 egulate T cell-dependent inflammation in the effector phase of CHS.

101 s in the initial stage and IgG2a Ab's at the effector phase of collagen-induced arthritis.

102 ratumoral myeloid cells did not suppress the effector phase of CTL.

103 In addition to caspase 3-like proteases, the effector phase of death involves the activation in the n

104 ssed by substantially fewer cells during the effector phase of disease and peaked during remission, w

105 CD8(+) T cell depletion in the effector phase of disease attenuated injury in murine an

106 nimize their suppressive activity during the effector phase of disease control.

107 al by CD40L is required early but not in the effector phase of disease development.

108 vity, we examined the effect of IL-27 at the effector phase of disease using adoptive transfer EAE.

109 that the blockade of cPLA(2)alpha during the effector phase of disease was more efficacious in amelio

110 to allow for study of the induction and the effector phase of disease, the adoptive EAE model was ch

111 stive of a harmful role of complement in the effector phase of disease.

112 intrathecal delivery of TGF-beta2 during the effector phase of EAE ameliorated disease severity.

113 r-deficient mice, IFN-gamma treatment during effector phase of EAE exacerbated disease.

114 ameliorating disease pathogenesis during the effector phase of EAE in the adoptive transfer model of

115 IL-27 can potently suppress the effector phase of EAE in vivo and, thus, may have therap

116 r, whether IL-27 influences the induction or effector phase of EAE is unknown.

117 t compensate for IL-23 deficiency during the effector phase of EAE.

118 ndicates that cPLA2alpha plays a role in the effector phase of EAE.

119 t-mediated events may occur early during the effector phase of EAE.

120 st that costimulation is required during the effector phase of EAT and that B7.2 may have opposing ro

121 ession associated with the sensitization and effector phase of EAU pathogenesis.

122 e contribution of GM-CSF specifically in the effector phase of EBA, disease was induced by transfer o

123 ion of MOG-reactive T cells, but also in the effector phase of encephalitogenic T cell activation wit

124 mulatory molecules that are important in the effector phase of experimental autoimmune uveitis (EAU).

125 intestinal inflammation and induction of the effector phase of food allergy.

126 g NTN, CCR1 expression profoundly alters the effector phase of glomerulonephritis.

127 milieu within the tumor lesion to boost the effector phase of immune responses in enhancing the anti

128 une responses are interesting models for the effector phase of immunity, in that granulomas can be pa

129 ss-presentation of tumor antigens during the effector phase of immunotherapy and suggest that approac

130 stimulatory CpG-ODNs strongly inhibited the effector phase of inflammatory arthritis in the K/BxN se

131 K/BxN serum-transfer system, focused on the effector phase of inflammatory arthritis.

132 ghting a new aspect of complement during the effector phase of inflammatory arthritis.

133 rs and it can be manipulated to activate the effector phase of innate immune responses.

134 igands (polyI:C/CpG) into a tumor during the effector phase of lentivector (lv) immunization effectiv

135 ts from experimental studies relating to the effector phase of Lewis rat EAN that may be relevant to

136 hich kinase inhibitors were added during the effector phase of lysis indicated that protein-tyrosine

137 ing a role for an NHL-2:CGH-1 complex in the effector phase of miRISC activity.

138 The effector phase of morphine-induced apoptosis appears to

139 nstrate a role for IL-12 and NK cells in the effector phase of murine SGVHD.

140 B:9-23 for both the initial priming and the effector phase of NOD anti-islet autoimmunity.

141 dendritic cells (DCs) may be involved in the effector phase of peanut-induced intestinal anaphylaxis.

142 To determine whether the effector phase of protection in vivo to the rodent paras

143 r mast cells in the mechanism underlying the effector phase of protective immunity against T. spirali

144 r capacity to recruit T cells to amplify the effector phase of pulmonary inflammation.

145 l mice, but was not sufficient to induce the effector phase of pulmonary inflammation.

146 of M effector functions that facilitate the effector phase of pulmonary inflammation.

147 or the proapoptotic Bcl-2 protein Bim in the effector phase of RA.

148 e mechanisms assume an important role in the effector phase of rejection once these cell-cytotoxic pa

149 NF-alpha is in wound-healing rather than the effector phase of rejection.

150 cells native to the lung contributes to the effector phase of some allergic responses.

151 ts from chronic stimulation that extends the effector phase of T cell activation, at the expense of T

152 ss-presented peptides can participate in the effector phase of T cell-mediated inflammatory responses

153 This helper role occurs during the effector phase of the anti-tumor immune response and is

154 ld be exploited to overcome obstacles at the effector phase of the antitumor immune response and impr

155 ole for chemokines in the development of the effector phase of the antitumor immune response has been

156 acts at the level of priming rather than the effector phase of the antitumor immune response.

157 The importance of CD4+ Th1 cells during the effector phase of the antitumor response has been oversh

158 le for this inflammatory mediator during the effector phase of the autoimmune process.

159 B7-2 does not impact the effector phase of the autoimmune response as adoptive tr

160 r DCs, Ag, and CD28 costimulation during the effector phase of the CD8(+) T cell response.

161 of IL-4 and IL-10, which interfere with the effector phase of the diabetic process.

162 f K/BxN T cell receptor transgenic mice, the effector phase of the disease is provoked by binding of

163 To study the role of B7 molecules in the effector phase of the disease, MOG 35-55-specific T line

164 n situ CD4(+) T cell accumulation during the effector phase of the disease.

165 litogenic responses during the tissue damage effector phase of the disease.

166 diation-resistant stromal cells promoted the effector phase of the disease.

167 g that loss of VIP specifically affected the effector phase of the disease.

168 r"-derived Treg were added at the priming or effector phase of the GVH response.

169 ning lymph nodes rather than suppressing the effector phase of the immune response in the periphery.

170 Treg can suppress antitumor immunity at the effector phase of the immune response induced by adoptiv

171 required only for tumor cell killing in the effector phase of the immune response.

172 suggesting a role for CD8(+) T cells in the effector phase of the immune response.

173 hages substantially outnumber AMs during the effector phase of the immune response; and accumulation

174 ope on virus-specific CD8 T cells during the effector phase of the primary cytotoxic T lymphocyte (CT

175 n skin allograft microvasculature during the effector phase of the rejection response.

176 required for the induction, maintenance, and effector phase of the Th1 response after LACK DNA vaccin

177 ather, CD4(+) T cells appeared to act at the effector phase of tumor rejection and responded to B16-d

178 ated a requirement for CD4(+) T cells in the effector phase of tumor rejection indicating a greater r

179 However, analysis of the effector phase of tumor rejection induced by vaccination

180 sms by which anti-LFA-1alpha Ab inhibits the effector phase of uveitis demonstrated that it blocks mu

181 elevant participants in both the priming and effector phases of acute graft rejection.

182 ells was determined in the sensitization and effector phases of allergic airway inflammation in mice.

183 regulatory function in the sensitization and effector phases of allergic asthma and to determine the

184 role at many levels of the sensitization and effector phases of allograft rejection.

185 ementary effects of radiation on priming and effector phases of antitumor immunity make it an appeali

186 7 and CTLA4-B7 interactions in induction and effector phases of antitumor immunity.

187 roles in stimulating both the initiation and effector phases of autoimmunity and that CD28 regulates

188 olvement of CMKLR1 in both the induction and effector phases of disease.

189 ce of B7 costimulators for the induction and effector phases of experimental autoimmune encephalomyel

190 ble mechanistic studies on sensitization and effector phases of humoral alloreactivity as well as eff

191 apeutic target that links the initiation and effector phases of humoral autoimmune disease.

192 e cytokines influence both the formative and effector phases of insulitis, it is critical to determin

193 Multiple pathways in both the priming and effector phases of melanoma rejection have been describe

194 nst paralysis, during both the induction and effector phases of relapsing experimental autoimmune enc

195 subunits and its receptor in the CNS at the effector phases of relapsing-remitting EAE including dis

196 cells are responsible for the induction and effector phases of SGVHD, the role of nonspecific effect

197 resenting cells (APC) during the priming and effector phases of T cells' function, and during natural

198 vely up-regulated during differentiation and effector phases of Th subsets.

199 oles for BRP-39/YKL-40 in the initiation and effector phases of Th2 inflammation and remodeling and s

200 Thus, NK cells operate in both induction and effector phases of the disease.

201 multisite manipulation of the initiation and effector phases of the IL-17 inflammatory network.

202 NA) pathway components in the initiation and effector phases of transposon silencing.

203 phils play a key role in the development and effector phases of type 2 immune responses in both aller

204 play an important role in the induction and effector phases of type 2 immune responses.

205 tical role in the induction, rather than the effector, phase of the disease.

206 activated T cells, extended a duration of an effector-phase of a specific immune response, and increa

207 uired at the inductive phase, but not at the effector phase, of the Th1 response within the infected

208 g resveratrol during either the induction or effector phase or through the whole course of EAE.

209 h antigen and costimulatory molecules at the effector phase raised an interesting question on the nat

210 progression, and their depletion during the effector phase, rather than priming phase, successfully

211 +) T cells expanding in the lungs during the effector phase require Ag, CD28 costimulation, and DCs f

212 es, respectively, but a role for Dectin-2 in effector phase responses has not been described.

213 llergen sensitisation, but restricts the Th2 effector phase responsible for inflammation.

214 host stromal cells, where it can inhibit the effector phase the immune response.

215 2) This effector phase was characterized by down-regulation of C

216 cted sensitized mice, demonstrating that the effector phase was targeted.

217 SF blockade were linked to modulation of the effector phase, whereas effects on early pathogenic even